C5 and age-related macular degeneration: A randomized, multicenter phase 2 trial comparing 5 mg monthly LFG316 injections with sham injections found no difference between the treatment and placebo groups in mean GA change from baseline or in visual acuity (NCT01527500) (Zamiri P. Complement C5 inhibition in AMD.